Skip to main content
Premium Trial:

Request an Annual Quote

Toronto Clinic to Offer PGXL's Warfarin Test to Canadian Clients

NEW YORK (GenomeWeb News) — The Medcan Clinic in Toronto will offer a genetic test that predicts patient response to the anti-clotting drug warfarin in Canada, under an agreement it signed with PGXL laboratories.
 
Medcan, a preventive health care clinic focused on identifying health risks before symptoms occur, said on Dec. 18 that it has signed an agreement with Louisville, Ky.-based PGXL to offer the warfarin test, which detects variations in the CYP2C9 and VCORC1 genes that are linked to warfarin response.
 
Medcan said that the agreement with PGXL also includes tests for “many other drug therapies,” but did not elaborate.
 
Medcan said that it is the first clinic to offer genetic testing for warfarin response in Canada. 
 
Financial terms of the agreement were not released.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.